Blood Res (2024) 59:11

Published online March 6, 2024

https://doi.org/10.1007/s44313-024-00010-0

© The Korean Society of Hematology

The role of next-generation sequencing in hematologic malignancies

Young‑Uk Cho1*

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‑Ro 43‑Gil, Songpa‑Gu, Seoul 05505, Korea

Correspondence to : *Young‑Uk Cho
yucho@amc.seoul.kr

Received: January 17, 2024; Accepted: February 13, 2024

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Abstract

Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.

Keywords Next-generation sequencing, Leukemia, Diagnosis, Prognosis, Monitoring

Article

REVIEW

Blood Res 2024; 59():

Published online March 6, 2024 https://doi.org/10.1007/s44313-024-00010-0

Copyright © The Korean Society of Hematology.

The role of next-generation sequencing in hematologic malignancies

Young‑Uk Cho1*

1Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‑Ro 43‑Gil, Songpa‑Gu, Seoul 05505, Korea

Correspondence to:*Young‑Uk Cho
yucho@amc.seoul.kr

Received: January 17, 2024; Accepted: February 13, 2024

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Abstract

Next-generation sequencing (NGS) allows high-throughput detection of molecular changes in tumors. Over the past 15 years, NGS has rapidly evolved from a promising research tool to a core component of the clinical laboratory. Sequencing of tumor cells provides an important step in detecting somatic driver mutations that not only characterize the disease but also influence treatment decisions. For patients with hematologic malignancies, NGS has been used for accurate classification and diagnosis based on genetic alterations. The recently revised World Health Organization classification and the European LeukemiaNet recommendations for acute myeloid leukemia consider genetic abnormalities as a top priority for diagnosis, prognostication, monitoring of measurable residual disease, and treatment choice. This review aims to present the role and utility of various NGS approaches for the diagnosis, treatment, and follow-up of hemato-oncology patients.

Keywords: Next-generation sequencing, Leukemia, Diagnosis, Prognosis, Monitoring

Table 1 . Genetic variants detectable by next-generation sequencing assay and of clinical utility in hematologic malignancies.

DiseasesMutated genesFusions
Myeloid malignanciesABL1, ANKRD26, ASXL1a,b, BCORa,b, BCORL1a, BRCC3a, CALRc, CBLa, CEBPAc, CTCFa, DDX41c, DNMT3Aa, ETNK1, ETV6c, EZH2b,c, FLT3c,d, GNASa, GNB1a, IDH1a,c, IDH2a,c, JAK2a,c, KITc, KMT2Ad, KRASa,c, MPLc, NPM1c, NRASa,c, PPM1Da, PTPN11a,c, RAD21c, RUNX1c, SETBP1a, SF3B1a,b,c, SH2B3, SRSF2a,b,c, STAG2b,c, TET2a, TP53a,c, U2AF1a,b,c, WT1c, ZBTB33a, ZRSR2bBCR::ABL1, CBFB::MYH11, DEK::NUP214, KMT2Ar, MECOMr, NUP98r, PML::RARA, RBM15::MRTFA, RUNX1::RUNX1T1,
Lymphoid malignancieseBRAF, CXCR4, CYLD, DIS3, EGR1, FAM46C, FGFR3, HIST1H1E, ID3, IRF4, KRAS, LTB, MAX, MYD88, NRAS, PAX5, RB1, STAT3, STAT5B, TCF3, TP53, TRAF3ABL1rf, ABL2rf, BCR::ABL1, CRLF2rf, CSF1Rrf, DGKHrf, DUX4r, EPORrf, ETV6::RUNX1, IGH::IL3, other IGHr, IL2RBrf, JAK2rf, KMT2Ar, MEF2Dr, MYCr, NTRK3rf, NUTM1r, PAX5r, PGDFRBrf, PTK2Brf, TCF3::PBX1, TCF3::HLF, TSLPrf, TYK2rf, ZNF384r

All genes are listed alphabetically.

a Genes commonly mutated in clonal hematopoiesis [1].

b Presence of mutations in these genes defines the category ‘acute myeloid leukemia myelodysplasia-related’ according to the WHO 2022 classification [1].

c Basic set of genes provided by the ELN guideline may be useful in a panel approach for measurable residual disease monitoring in acute myeloid leukemia [18].

d Reliable detection of FLT3-internal tandem duplication or KMT2A-partial tandem duplication using targeted NGS assay may require specialized bioinformatics analysis.

e Only genetic aberrations in blood- or bone marrow-derived lymphoid malignancies were considered.

f These genes are typically involved in gene fusions that characterize BCR::ABL1-like features.


Blood Res
Volume 60 2025

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download